Shared on 01 May 25
Fair value Decreased 5.09%Proton Therapy Expansion Will Transform Global Cancer Treatment
Shared on 24 Apr 25
Fair value Decreased 3.41%Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments
AnalystConsensusTarget has decreased revenue growth from 13.1% to 9.3%, decreased profit margin from 9.3% to 6.4% and increased future PE multiple from 9.9x to 15.5x.
Shared on 17 Apr 25
Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 9.08%Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 3.14%Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments
Shared on 26 Mar 25
Fair value Decreased 7.66%Actinium-225 Production Expansion Will Capitalize On Next-Generation Cancer Treatments
AnalystConsensusTarget has increased revenue growth from 6.7% to 7.5%.